

MSD

Merck Sharp & Dohme (Australia) Pty Limited
ABN: 14 000 173 508
Level 1 - Building A, 26 Talavera Road
Macquarie Park NSW 2113
North Ryde Post Business Centre
Locked Bag 2234 North Ryde, NSW, 1670
T 02 8988 8000
F 02 8988 8001
msd-australia.com.au



Ms Ivone Johnson
Executive Officer
ANZBMS / ESA
145 Macquarie Street
SYDNEY NSW 2000

5th April 2016

Notice of cessation of supply of FOSAMAX[®] (alendronate sodium) 40 mg tablets

Dear Ms Johnson,

We would like to inform you that MSD have decided to discontinue the supply of FOSAMAX[®] 40 mg in Australia. It is anticipated that there will continue to be supply of these tablets in Australia until mid-2016 but this may change if there is a significant increase in demand.

The company's decision to discontinue FOSAMAX[®] 40 mg is based on the fact that current usage has declined to only 5% of former usage and it is no longer sustainable to continue to supply in Australia. Please note that there is no impact to the quality or safety of the tablets currently in use by patients. FOSAMAX[®] 40 mg can continue to be used until all stock is depleted or has expired.

MSD apologises for the difficulties that this decision may cause your members and their patients and appreciates the complex range of issues that may need to be managed with some patients, especially those with limited treatment alternatives.

Should you have any questions, please do not hesitate to contact MSD on 1800 818 553.

Yours sincerely

A handwritten signature in blue ink, appearing to read "Gary Jankelowitz", is written over a light blue horizontal line.

Gary Jankelowitz
Medical Director